Abstract
Positron-emission tomography (PET) with 18-fluorodeoxyglucose has a role in the diagnosis and staging of lung cancer, but is also appealing for assessment of prognosis and treatment. A systematic search of the published work shows good evidence that [(18)F]FDG uptake on PET has independent prognostic value in newly diagnosed non-small-cell lung cancer. PET is a sensitive method of measuring the biological effects of anticancer therapy, but until better standardisation and large-scale experience is available, it should only be used for additional assessments of early response in clinical trials. Further studies are needed to define the role of [(18)F]FDG-PET in restaging after induction therapy in multimodality approaches for locally advanced lung cancer. The assessment of prognosis by [(18)F]FDG-PET is less substantiated in treated lung cancer than in newly diagnosed patients. Good prospective evidence documents the effectiveness of [(18)F]FDG-PET over CT in the correct identification of recurrent lung cancer.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | The Lancet Oncology |
| Vol/bind | 5 |
| Udgave nummer | 9 |
| Sider (fra-til) | 531-40 |
| Antal sider | 10 |
| ISSN | 1470-2045 |
| DOI | |
| Status | Udgivet - sep. 2004 |
| Udgivet eksternt | Ja |